HOTH ข่าวฟอเร็กซ์
Hoth Therapeutics Partners Altasciences For Study On HT-KIT Cancer Treatment
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday that it has completed bioanalytical method development under its prior agreement with Altasciences.
RTTNews
|
324 วันที่ผ่านมา
Hoth Therapeutics' Pre-IND Submission For HT-KIT For Advance Systemic Mastocytosis Accepted By FDA
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Monday it has submitted a request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM), a rare aggressive form of cancer.
RTTNews
|
492 วันที่ผ่านมา
Hoth Therapeutics Says FDA Accepts IND Application For HT-001 For Treatment Of Cancer Disorders
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy.
RTTNews
|
748 วันที่ผ่านมา
Hoth Therapeutics Partners Altasciences For Manufacturing HT-TBI For Traumatic Brain Injury/Stroke
Biopharmaceutical company Hoth Therapeutics, Inc. (HOTH) announced Tuesday that it has signed an agreement with Altasciences, a fully integrated early phase CRO/CDMO, to develop and manufacture the HT-TBI drug product formulation.
RTTNews
|
848 วันที่ผ่านมา
